Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Pfenex in a research report on Monday, October 28th.
PFNX stock traded down $0.17 during trading on Wednesday, reaching $11.14. 164,246 shares of the company’s stock were exchanged, compared to its average volume of 360,762. Pfenex has a 1-year low of $3.40 and a 1-year high of $13.95. The company has a fifty day simple moving average of $11.82.
Pfenex Company Profile
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.
Read More: What is the definition of arbitrage?
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.